You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

D2C7

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Newly Diagnosed MGMT Unmethylated Glioblastoma Trial in Durham (D2C7-IT, 2141-V11)

Not yet recruiting
  • Newly Diagnosed MGMT Unmethylated Glioblastoma
  • Durham, North Carolina
    Duke University Medical Center
Feb 7, 2023

Malignant Glioma, Brain Tumor, Recurrent Trial in Durham (D2C7-IT)

Active, not recruiting
  • Malignant Glioma
  • Brain Tumor, Recurrent
  • Durham, North Carolina
    Preston Robert Tisch Brain Tumor Center at Duke
Jul 12, 2022

Glioma, Malignant Trial in Durham (D2C7-IT, 2141-V11)

Recruiting
  • Glioma, Malignant
  • Durham, North Carolina
    Duke University Medical Center
Jul 27, 2022

Malignant Glioma Trial in Durham (D2C7-IT (6920 ng/mL via convection-enhanced delivery), Atezolizumab (1200 mg every three

Recruiting
  • Malignant Glioma
  • D2C7-IT (6920 ng/mL via convection-enhanced delivery)
  • +2 more
  • Durham, North Carolina
    Duke University Medical Center
Mar 22, 2022

Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, NSCLC Trial (ELI-002 7P)

Not yet recruiting
  • Pancreatic Ductal Adenocarcinoma
  • +14 more
  • ELI-002 7P
  • (no location specified)
Feb 3, 2023

Aortic Valve Stenosis, Multidetector Computed Tomography, Vitamin K 2 Trial in Odense (Menaquinone-7 720 µg/day including the

Completed
  • Aortic Valve Stenosis
  • +3 more
  • Menaquinone-7 720 µg/day including the recommended daily dose of vitamin D (25 µg/day).
  • Placebo
  • Odense, Odense C, Denmark
    Department of Cardiology, Odense University Hospital
Sep 28, 2022

Covid19 Trial in Ottawa (drug, dietary supplement, other)

Suspended
  • Covid19
  • Vitamin D3 50,000 IU
  • +4 more
  • Ottawa, Ontario, Canada
    The Centre for Health Innovation
Aug 8, 2022

Disease Activity in Canadian Adult Moderate-to-Severe Atopic

Recruiting
  • Atopic Dermatitis
    • Calgary, Alberta, Canada
    • +17 more
    Jan 17, 2023

    B Acute Lymphoblastic Leukemia Trial (procedure, biological, drug, radiation)

    Not yet recruiting
    • B Acute Lymphoblastic Leukemia
    • Biospecimen Collection
    • +19 more
    • (no location specified)
    Nov 8, 2023

    BRAF NP_004324.2:p.V600X, KRAS wt Allele, Metastatic Malignant Solid Tumor Trial in Houston (biological, drug, other)

    Active, not recruiting
    • BRAF NP_004324.2:p.V600X
    • +6 more
    • Cetuximab
    • +4 more
    • Houston, Texas
      M D Anderson Cancer Center
    Sep 22, 2022

    Acute Myeloid Leukemia Trial in Seattle (drug, biological, other)

    Active, not recruiting
    Has Results
    • Acute Myeloid Leukemia
    • Seattle, Washington
      Fred Hutch/University of Washington Cancer Consortium
    Oct 10, 2022

    Impaired Glucose Tolerance Trial in Sherbrooke (drug, other, procedure)

    Completed
    • Impaired Glucose Tolerance
    • Nicotinic acid
    • +4 more
    • Sherbrooke, Quebec, Canada
      centre de recherche du CHUS
    Nov 16, 2021

    Mantle Cell Lymphoma Trial in United States (Acalabrutinib, Bortezomib, Cyclophosphamide)

    Recruiting
    • Mantle Cell Lymphoma
    • New Orleans, Louisiana
    • +5 more
    Dec 13, 2022

    Philadelphia Chromosome Negative, Recurrent B Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia Trial in

    Terminated
    Has Results
    • Philadelphia Chromosome Negative
    • +2 more
    • Blinatumomab
    • +11 more
    • Houston, Texas
      M D Anderson Cancer Center
    Nov 3, 2022

    T Acute Lymphoblastic Leukemia, T Lymphoblastic Lymphoma Trial in Houston (Cyclophosphamide, Cytarabine, Dexamethasone)

    Recruiting
    • T Acute Lymphoblastic Leukemia
    • T Lymphoblastic Lymphoma
    • Houston, Texas
      M D Anderson Cancer Center
    Jan 11, 2023

    Hepatitis B, Chronic Trial in Worldwide (JNJ-73763989, PegIFN-alpha-2a, Tenofovir disoproxil)

    Terminated
    • Hepatitis B, Chronic
    • Hillsborough, New Jersey
    • +11 more
    Dec 28, 2022

    People Who Have Genetic Changes and Features of Autism: Simons

    Recruiting
    • 16P11.2 Deletion Syndrome
    • +184 more
      • New York, New York
      • +1 more
      Jan 6, 2023

      Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Tumor, Acute Myeloid

      Not yet recruiting
      • Acute Myeloid Leukemia
      • +3 more
      • (no location specified)
      Nov 15, 2022

      Breast Cancer Trial in United States (Capecitabine, Neratinib, EORTC QLQ - BR23, EQ-5D-5L, EORTC QLQ-C30)

      Active, not recruiting
      • Breast Cancer
      • Hartford, Connecticut
      • +9 more
      Apr 15, 2022

      Recurrent B Acute Lymphoblastic Leukemia, Recurrent Ph-Like Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic

      Terminated
      Has Results
      • Recurrent B Acute Lymphoblastic Leukemia
      • +3 more
      • Houston, Texas
        M D Anderson Cancer Center
      Apr 28, 2022

      B Acute Lymphoblastic Leukemia, Ph-Like Acute Lymphoblastic Leukemia Trial in Duarte (Cyclophosphamide, Cytarabine, Daunorubicin

      Recruiting
      • B Acute Lymphoblastic Leukemia
      • Ph-Like Acute Lymphoblastic Leukemia
      • Duarte, California
        City of Hope Medical Center
      Jul 26, 2022

      Obesity, Morbid, Bariatric Surgery, Adolescent Trial in Aurora (Phentermine, Immediate Release Topiramate, Placebo for

      Completed
      • Obesity, Morbid
      • +4 more
      • Aurora, Colorado
        Children's Hospital Colorado
      Mar 7, 2022

      Chronic Migraine Trial in Worldwide (KOS (Intranasal kinetic oscillation stimulation))

      Not yet recruiting
      • Chronic Migraine
      • KOS (Intranasal kinetic oscillation stimulation)
      • Dresden, Germany
      • +14 more
      Apr 25, 2023

      Oral Upadacitinib Tablets to Assess Change in Disease Symptoms

      Recruiting
      • Rheumatoid Arthritis (RA)
        • Edmonton, Alberta, Canada
        • +38 more
        Jan 17, 2023

        ALS, FTD Trial in Worldwide (WVE-004, Placebo)

        Active, not recruiting
        • ALS
        • FTD
        • North Ryde, New South Wales, Australia
        • +16 more
        Feb 2, 2023